PMV Pharmaceuticals (PMVP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors: David H. Mack, Ph.D. and Laurie Stelzer, with board recommendation to vote for both.
Advisory vote on executive compensation, with board recommendation to approve.
Ratification of Ernst & Young LLP as independent public accounting firm, with board recommendation to approve.
Other business may be addressed as appropriate during the meeting or any adjournment.
Board of directors and corporate governance
Board recommends the election of two nominees to serve as Class III directors.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding advisory basis, the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from PMV Pharmaceuticals
- Ovarian cancer data support a planned 1Q2027 rezatapopt NDA, with cash runway into 1Q2028.PMVP
Corporate presentation - Rezatapopt’s 46% ovarian ORR, $46.9M net offering and planned Q1 2027 NDA.PMVP
Q3 2026 - Rezatapopt demonstrates strong efficacy in PROC with launch and expansion plans well underway.PMVP
H.C. Wainwright 28th Annual Global Investment Conference - Phase 2 trial completed, NDA planned Q1 2027, cash runway into Q2 2027, funding risks persist.PMVP
Q2 2026 - Interim phase II data for Y220C p53 solid tumors expected July-August, with robust enrollment.PMVP
TD Cowen's 6th Annual Oncology Innovation Summit - Directors elected, executive pay approved, and auditor ratified; all proposals passed.PMVP
AGM 2026 - Q1 2026 net loss was $18.0M; cash runway extends through Q2 2027 as rezatapopt advances in trials.PMVP
Q1 2026 - Rezatapopt shows 46% ORR in ovarian cancer; NDA submission planned for Q1 2027.PMVP
TD Cowen 46th Annual Health Care Conference - Director elections, executive pay, and auditor ratification headline the annual meeting agenda.PMVP
Proxy filing